A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL) (NCT01716806)
This is an open-label, multicenter, phase 2 clinical trial designed to evaluate the efficacy and safety of the antibody-drug conjugate brentuximab vedotin as a single-agent (Part A) and in combination with dacarbazine (Part B) or bendamustine (Part C) in front-line therapy of Hodgkin lymphoma in adults age 60 and above.
This trial is sponsored by Seattle Genetics. 
- Condition: Lymphoma
- Phase: II
- Estimated Enrollment: 70
- Start: October 2012
- Estimated Completion: October 2018
- Last verified: June 2015
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.